Objective: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. Methods: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. Results: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. Conclusions: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.
Introduction
Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death worldwide [Soriano, 2007; Chapman et al. 2006; Halpin and Miravitlles, 2006] , The prevalence of COPD in the general population is estimated to be approximately 1% across all ages, and increases to >10% when only those aged 40 years are considered [Chapman et al. 2006 ]. In men over 65 years of age this may rise to 20% [Sobradillo Peñ a et al. 2000] . Despite advances in management, the prevalence and associated disease burden are expected to increase in coming years due to continued exposure to contributory risk factors and the increasing age of the world's population. Existing prevalence data show that COPD and the associated morbidity and mortality vary across countries [Miravitlles et al. 2008b; Buist et al. 2007 ] and across different groups within countries [Sobradillo Peñ a et al. 2000 ]. Furthermore, there are limited data comparing patients' demographic characteristics and treatments between geographic regions.
For patients, their families and carers, the burden of COPD is also high, particularly in terms of health-related quality of life [Llor et al. 2008; Miravitlles, 2007a; Miravitlles et al. 2004 ]. Elderly patients with COPD are markedly inactive in daily life compared with healthy elderly individuals [Pitta et al. 2005] , and this correlates strongly with hospitalisations and mortality [Garcia-Aymerich et al. 2006 ]. Furthermore, intermittent acute exacerbations contribute significantly to the burden and progression of disease [Donaldson et al. 2002] . In patients with COPD, more frequent exacerbations lead to more rapid deterioration in lung function [Donaldson et al. 2002] ; health-related quality of life [Seemungal et al. 1998 ], even in more mildly affected patients [Llor et al. 2008] ; and mortality increases with the frequency of severe exacerbation [Soler-Cataluñ a et al. 2005] .
The results of recent clinical trials have shown that treatment with moxifloxacin is highly effective and well tolerated by patients with acute exacerbations of chronic bronchitis (AECB) or COPD. Several studies have shown that moxifloxacin therapy is associated with favourable outcomes [Miravitlles et al. 2007c; Niederman et al. 2006; Wilson et al. 2004] and faster recovery in both AECB and acute exacerbations of COPD than standard antibiotic therapy [Miravitlles et al. 2005] .
A large prospective, multicentre, non-interventional post-marketing study the Greatest International ANtibiotic Trial (GIANT) was performed in Asia, Europe, Latin America, the Middle East and Africa. The aims of the study were to gain further information on the characteristics of AECB patients in a large sample gathered from multiple countries around the world, and to assess the impact on daily life of AECB and the effect of treatment with moxifloxacin in routine clinical practice.
This report describes patient characteristics, risk factors for, and characteristics of exacerbations, and the impact of exacerbations on daily life in eight European countries included in the study. We also assessed the effectiveness of treatment with moxifloxacin.
Methods

Study design
This was a multicentre, non-interventional observational study that collected data from February 2004 to December 2006. Countries from Europe, the Middle East, Africa, Asia Pacific and Latin America were involved. Data for patients from eight European countries (Austria, Croatia, Germany, Hungary, the Netherlands, Poland, Slovenia and Switzerland) are presented here.
Ethical conduct of the study
The study was carried out within an approved indication in accordance with guidelines from the European Medicines Agency and the US Food and Drug Administration and applicable local law(s) and regulation(s) for non-interventional studies. Written informed consent was obtained from patients according to the respective local laws and regulations if applicable.
As this study was non-interventional, only examinations selected by the physician were conducted, and no additional investigations were performed as a result of participation in this study. The study was filed with the local competent regulatory and federal authorities, independent review boards, and independent ethics committees, where required.
Patients
Data for patients aged 35 years with a diagnosis of AECB who were treated as outpatients with oral moxifloxacin according to the clinical judgement of the attending physician are presented here. An exacerbation was considered when the patient experienced an acute increase in respiratory symptoms: dyspnoea, sputum volume and/or sputum purulence. Patients with stable spirometry results showing a ratio FVC/FEV 1 <70% were considered to be suffering from COPD (Rabe et al. 2007) . All clinical decisions about selection and implementation of individual medical treatment and diagnostic measurements were made exclusively by the participating physicians. Exclusion criteria were contraindications to the use of moxifloxacin as per prescribing information.
Study procedures
For each patient, data on clinical history, concomitant diseases, previous treatments, diagnosis of current exacerbation, moxifloxacin treatment, concomitant medication, and clinical symptoms (fever, cough, dyspnoea, chest discomfort, fatigue and sleep disturbance, sputum volume and colour) were recorded at enrolment. Exacerbations were classified into types 1, 2 and 3 according to the presence of three, two or only one of the three cardinal symptoms originally described by Anthonisen et al. (1987) (increased sputum volume, increased sputum purulence and worsened dyspnoea) at initial visit. Follow-up visits were done within an average of 14 days, and patient symptoms, changes in concomitant medication and any adverse events were recorded. Information about the previous AECB episode was collected by patient memory recall, not from clinical records.
An optional supplementary patient questionnaire was included in the study at the discretion of individual national study committees (it was not used in Austria and Switzerland). This questionnaire was issued to patients at enrolment for completion at the end of treatment with moxifloxacin. On this questionnaire patients were asked to report the duration of moxifloxacin intake, the severity of disturbance of sleep and of normal daily activities during treatment, the duration of disruption of normal activities and/ or performance due to the current exacerbation, how long after starting treatment they felt better and healthy, and how moxifloxacin therapy compared with the treatment they received for their previous episode.
Study analyses
Descriptive analyses of the data were performed using summary statistics for categorical and quantitative data. Continuous data were described for non-missing values by mean, standard deviation, minimum and maximum. Differences between subgroups of patients were analysed using tests of significance (Fisher's exact test, Welch's two sample t-test, Pearson's 2 test).
Results
Patient population
Baseline characteristics at time of inclusion are presented in Table 1 for 9225 patients aged 35 years from eight European countries (Austria, Croatia, Germany, Hungary, the Netherlands, Poland, Slovenia and Switzerland). Valid completed questionnaires were obtained from 6358 patients.
Almost two-thirds of patients were either current or ex-smokers. Overall, more than half of patients had suffered from chronic bronchitis for up to 10 years. Approximately half of all patients were treated by a family doctor (51.9%) ( Table 1) . Patients had experienced an average of 2.2 exacerbations in the previous 12 months. The comorbid conditions present most frequently were cardiac disease (33%), such as cardiac ischaemia (14%) and cardiac insufficiency (13%), and diabetes mellitus (15%).
Patients were oldest, on average, in Croatia, Slovenia and Poland. In Croatia and Slovenia over 60% of patients were male. The proportion of patients suffering from chronic bronchitis for longer than 10 years was lowest in Austria. In some of the Eastern European countries (Croatia, Slovenia, Hungary and Poland) patients had on average more AECB and hospitalisations in the past 12 months, had more disturbance of daily activities and sleep due to their last AECB, and were more likely to have a current Anthonisen type 1 exacerbation compared with patients in countries of Western Europe (Table 1) .
The proportion of smokers was approximately 30% in five countries but lower in Slovenia (23.1%) and higher in Hungary (40.8%) and in Switzerland (50.1%) ( Table 1 ). The proportion of non-smokers in Austria (41.2%) and Germany (43.6%) was approximately twice that in Slovenia (21.4%) and Switzerland (21.0%). Slovenia showed the highest rate of past smokers (53.6%) compared with all other countries.
A total of 3242 patients (35.1%) had an FEV 1 measurement recorded at time of inclusion [mean (SD), 1.8 (0.8) l]. Patient characteristics were generally similar whether an FEV 1 measurement was recorded or not (Table 2 ). However, of those patients with FEV 1 measurement, more had suffered for longer than 10 years from chronic bronchitis than patients with no FEV 1 value recorded (39.0% vs 25.1%; p < 0.001).
FEV 1 was assessed in fewer patients treated by GPs (15.5%) compared with those treated by chest specialists (66.7%; p < 0.001). Patients treated by chest specialists were more likely to have lower mean FEV 1 values, more comorbid conditions, longer duration of chronic bronchitis and more severe disease and they were more likely to experience an Anthonisen type 1 exacerbation compared with patients treated by GPs (p < 0.001 for all comparisons).
Patients 65 years or older vs younger patients
There was a clear trend of older patients (65 years) suffering from chronic bronchitis for a longer period; older patients also had a lower mean FEV 1 (1.5 vs 2.0 l; p < 0.001) ( Table 2 ). The previous exacerbation had more impact on older patients, who tended to have more days with daily activities affected and more nights with sleep disturbed than younger patients. Younger patients were more often smokers (39.9% vs 18.6%; p < 0.001) ( Table 2) . 
Characteristics of patients by Anthonisen type of AECB
Comparisons were performed between patients with antibiotic indication (types 1 and 2) and those without antibiotic indication (type 3). Patients with an Anthonisen type 1 or 2 AECB were more likely to be male and were on average older than those with Anthonisen exacerbations type 3 (Table 3 ). The current AECB was classified as type 1 in 50.2% of those who had an FEV 1 measurement compared with 33.7% of those with no FEV 1 value (Table 2) . Compared with patients with type 3 AECB, patients with types 1 or 2 exacerbation had lower mean FEV 1 (1.7 vs 1.9 l; p < 0.001) and had a higher average number of exacerbations in the last 12 months (2.3 vs 2.0; p < 0.001) (Table 3) . Significantly more patients experiencing type 1 or type 2 exacerbations were current or ex-smokers (p < 0.001) (Table 3 ) and had a longer duration of chronic bronchitis (p < 0.001). Anthonisen type 1 and 2 exacerbations were also associated with a significantly greater impact of the disease, including the number of exacerbations, physician visits and hospitalisations in the past 12 months, compared with type 3 AECB (p < 0.001).
For the last exacerbation, patients affected by
Anthonisen type 1 or 2 AECB also experienced significantly greater disturbance of daily activities and sleep than those with type 3 episodes (p < 0.001) (Table 3) .
Treatment efficacy
The majority of patients received moxifloxacin for 5 days (45.9%), 7 days (32.5%) or 10 days (17.1%). Patients took a mean (SD) of 3.4 (1.8) days to improve and 6.3 (3.1) days to recover from the current AECB with moxifloxacin ( Table 4 ). The responses obtained by the patient questionnaire concurred with the physicians' assessment of therapy; efficacy was rated as good or very good by 94.9% of patients, 94.2% of patients felt better (mean 3.4 days) and mean time to recovery was 7.3 days (Table 4 ).
Adverse events
Tolerability was considered good or very good in 96.7% of patients. Of the 9225 patients, 241 (2.6%) experienced one or more adverse event, and in 141 of these (1.5%) the adverse event was judged to be treatment related. The predominant treatment-related adverse events were gastrointestinal (89 patients; 52 experienced diarrhoea, 31 nausea, 11 vomiting). No previously unreported adverse events were documented. Serious adverse events, which generally resolved or improved, occurred in 67 patients (0.7%) and were judged by the physician to be treatment related in seven patients (hypersensitivity 2, urticaria 1, cardiac failure 1, ineffective drug 1, anaphylactic reaction 1, vulvovaginal mycotic infection 1). The patient with cardiac failure (a 79-year-old female), who also had metastatic lung cancer, died 19 days after the moxifloxacin therapy. In the case follow-up carried out after database lock the cause of death was confirmed by the treating physician to be cardiac failure and was judged not to be related to treatment. Adverse event-related withdrawals from treatment were rare, with only 57/9225 (0.6%) patients permanently discontinuing treatment for this reason.
Discussion
This study is the largest global investigation of the course and impact of episodes of exacerbations in outpatients conducted to date and allows a comparison of patient characteristics in AECB across different cultures and regions as well as outcome of moxifloxacin treatment in routine clinical practice. This paper presents data from the European region and, to our knowledge, is the first to report data on characteristics of patients with AECB from Eastern Europe.
Consistent with previous studies [Miravitlles and Llor, 2007; Koch et al. 2004; Landen et al. 2001] , more male patients than female patients were treated for AECB in this study overall. This difference was not large, however, and in Austria, Hungary and the Netherlands the proportions of male and female patients were similar. In the past, studies have shown that COPD prevalence and mortality were greater among men than women [Soriano, 2007; Sobradillo Peñ a et al. 2000 ]. Changing patterns of tobacco smoking, with increased rates of cigarette smoking in females [Sobradillo Peñ a et al. 2000 ], has contributed to an increase in the prevalence of chronic bronchitis and COPD among women.
A mean of 30.6% of patients treated for AECB in this study were current smokers. In Germany, the proportion of current smokers and ex-smokers (55%) was higher than found previously (43%) [Landen et al. 2001 ]. However, when comparing different countries, the proportion of patients who had previously smoked was between 22% and 54%, which may reflect cultural differences. The variation in the proportion of smokers and ex-smokers treated in the study may also reflect environmental or ethnic differences, as shown by a recent study in which elderly Mexican Americans were found to have similar severities of COPD despite less tobacco exposure than European Americans [Adams et al. 2006 ]. The high prevalence of concomitant diseases, such as cardiovascular disorders, has also been noted in patients with AECB and has important prognostic implications ].
Despite over one-third of patients being life-long non-smokers, the number of exacerbations experienced in the previous 12 months was relatively high (2.2 exacerbations). As the study recruited patients who were currently suffering an exacerbation, it is likely that it also selected for patients who were prone to suffering further exacerbations. Acute exacerbations appear to have a significant impact on patient quality of life, including psychological well-being, and this may be underestimated by clinicians [Kessler et al. 2006 ]. Hospitalisation due to acute exacerbations accounts for 4060% of the total cost of an AECB [Anzueto, 2006] , and patients with more severe disease are at increased risk of hospitalisation due to therapeutic failure ].
Routine spirometry, specifically including measurement of FEV 1 , is an important tool in the diagnosis, staging and management of patients with COPD and has been recognised as a ''gold standard'' for diagnosis by many guidelines [Rabe et al. 2007 ]. Spirometry is not only useful for staging disease, but also excluding a diagnosis of COPD in patients with similar clinical presentations and guiding treatment choices [Derom et al. 2008] . For patients hospitalised due to exacerbations of COPD, a low FEV 1 measured at admission and over the first several days of hospitalisation is strongly associated with poor clinical outcomes [Niewoehner et al. 2000 ].
This study provides evidence in support of the perception that FEV 1 is not measured routinely in any country, but that it is more likely to be assessed in patients with established respiratory disease. It is probable that patients more severely ill with AECB would be seen by a chest physician while mild cases would be seen by GPs/family doctors without further referral to a specialist. In this study, FEV 1 was measured in only 16% of patients treated by a GP or family doctor. The under-use of spirometry to guide diagnosis and treatment by primary care physicians has been noted elsewhere and highlights potential gaps in the knowledge of guidelines for the management of COPD [Miravitlles et al. 2007d ].
Spirometry and categorisation by Anthonisen score are additional tools to help with the management of COPD. According to ERS guidelines [Woodhead et al. 2005] , antibiotics should only be prescribed to patients with Anthonisen type 1 exacerbations, or type 2 exacerbations where purulent sputum is present. In the current study, over 20% of patients presented with a type 3 exacerbation and received antibiotic therapy. As the trial was non-interventional, the prescribing choice was left to the physician.
The results, therefore, suggest that in some circumstances, therapy was not being prescribed in accordance with guidelines.
There is now good evidence that treatment with fluoroquinolones such as moxifloxacin prolongs exacerbation-free intervals, especially in older and more severely ill patients [Wilson et al. 2006 [Wilson et al. , 2004 . Across treatment guidelines, moxifloxacin is generally recommended as a first-line treatment option for patients presenting with multiple risk factors for poor outcome, such as severe impairment of lung function, comorbid disease(s), or frequent exacerbations, or as a second-line treatment option for patients who experience initial treatment failure [Miravitlles et al. 2008a; Miravitlles, 2007b; Woodhead et al. 2005 ].
In the PERCEIVE study, a random telephone contact survey study performed in five European countries and the USA, more than half of the 1107 patients interviewed wished to receive treatments that provide quicker relief of symptoms of exacerbations and also for treatments that prolong periods between flare-ups [Miravitlles et al. 2007a ]. Consistently, the results of the current study show that AECB have a major impact on patients' daily lives. Across different countries, patients took a mean of 3.4 days to improve and 6.3 days to recover. However, it is important to identify patients with risk factors for long recovery to be more closely followed up.
Confirming previous assessments of the effectiveness and speed of moxifloxacin therapy [Miravitlles et al. 2005 [Miravitlles et al. , 2003 Landen et al. 2001 ], 97% of patients in this study considered that treatment with moxifloxacin had been helpful. Treatment was well tolerated; adverse events were comparable in frequency to that found in previous studies [Koch et al. 2004; Landen et al. 2001 ]. In addition, over 94% of physicians considered efficacy and tolerability of moxifloxacin therapy to be good or very good and in approximately 98% of patients, physicians were satisfied or very satisfied with the effectiveness of treatment.
The results of the GIANT study provide a useful insight into the effects of exacerbations on daily life activities and the role of moxifloxacin as a therapy prescribed in routine practice. It should, however, be emphasised that this is an observational study, not a randomised controlled trial (RCT) and that there are certain limitations inherent to this type of study design. A key criticism of noninterventional or observational studies is the lack of patient randomisation and strict inclusion and/ or exclusion criteria [Black, 1996] . However, this lack of patient pre-selection may mean that compared with RCTs, the study population better reflects that of the real-life population in terms of age, sex and disease severity [Hannan, 2008] . Indeed, the greater ''generalisability'' of observational data has been noted as a specific strength of observational studies compared with RCTs [Yu, 2009; Black, 1996] . A specific limitation of the GIANT study was that no comparison of efficacy of moxifloxacin with other antibiotics is possible and some patients with type 3 exacerbations were also included; therefore, indicating that guidelines are not followed in a significant number of cases.
The data in the GIANT study relied on subjective assessments (either the patient's recall or the physician's judgement of an event) and this should be taken into account when interpreting any efficacy data. Nonetheless, the study does provide information on many patients over an extended time that it may not have been possible to collect within the scope of an RCT.
In conclusion, this global non-interventional investigation provides a detailed real-life perspective on the characteristics of patients with exacerbations of chronic bronchitis and COPD, the impact of these episodes and patients' response to treatment. The preliminary results from over 9200 patients in the European region of the GIANT study show that patients with exacerbations have different characteristics across countries and different exposures to risk factors, particularly smoking. Exacerbations have a significant negative impact on the lives of those affected, causing disturbance of daily activities and sleep as well as multiple physician visits and, for some, hospitalisation. Data collected during this noninterventional study carried out in a real-life setting reinforce results from previous studies, that moxifloxacin is a valuable treatment option for patients with exacerbations. These preliminary results reinforce the established safety and tolerability profile of moxifloxacin in a 'real-life' setting.
Summary
The GIANT study facilitated analysis of the characteristics of the largest European population of patients with AECB and AE-COPD examined to date. Treatment with moxifloxacin was effective in providing fast resolution of symptoms and was well tolerated. Large differences in the clinical characteristics of patients and different exposures to respiratory risk factors across countries have been described. Spirometry is underused, particularly in primary care.
